D r. George Tidmarsh, the FDA drug regulator who was placed on leave and complained of a “toxic” work environment in an ...
George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...
The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on ...
In any review of mifepristone, the FDA will now have to grapple with Judge Otake’s conclusion that the 2023 REMS decision for ...
George Tidmarsh, MD, PhD, director of the FDA’s Center for Drug Evaluation and Research, resigned Nov. 2 after being placed on administrative leave, The New York Times reported Nov. 2. Dr. Tidmarsh ...
We wanted to know where a widely used prescription drug that treats high cholesterol was manufactured and whether the factory ...
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB ...
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading ...
Dr. George Tidmarsh, the FDA's top drug regulator, was placed on leave amid controversy over the drug approval process and a battle with a business foe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback